Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx

Autor: Pentheroudakis, G., Nicolaou, I., Kotoula, V., Fountzilas, E., Markou, K., Eleftheraki, A.G., Fragkoulidi, A., Karasmanis, I., Tsigka, A., Angouridakis, N., Vlachtsis, K., Nikolaou, A., Pavlidis, N., Fountzilas, G.

Publikováno v: In Oral Oncology August 2012 48(8):709-716

Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non–nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group

Autor: Fountzilas, G. ^*, Papakostas, P., Dafni, U., Makatsoris, T., Karina, M., Kalogera-Fountzila, A., Maniadakis, N., Aravantinos, G., Syrigos, K., Bamias, A., Christodoulou, C., Economopoulos, T., Kalofonos, H.P., Nikolaou, A., Angouridakis, N., Stathopoulos, G., Bafaloukos, D., Pavlidis, N., Daniilidis, J.

Publikováno v: In Annals of Oncology October 2006 17(10):1560-1567

Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx

Autor: Pentheroudakis, George, Nicolaou, I., Kotoula, V., Fountzilas, E., Markou, K., Eleftheraki, A. G., Fragkoulidi, A., Karasmanis, I., Tsigka, A., Angouridakis, N., Vlachtsis, K., Nikolaou, A., Pavlidis, Nicholas, Fountzilas, George

Publikováno v: Oral oncology

Angiogenesis is active in localised laryngeal squamous cell carcinoma. We assessed relative messenger RNA (mRNA) and immunohistochemical (IHC) expression of Vascular Endothelial Growth Factors (VEGF) A, B, C, their receptors VEGFR1, 2, 3, Neuropilins

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df6634fdb1ced93fe4f4b763c28cbac1
https://pubmed.ncbi.nlm.nih.gov/22366437

Olfaktorische Funktion bei allergischer Rhinitis

Autor: Yakinthou, A, Angouridakis, N, Constantinidis, J

Publikováno v: 77. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf-und Hals-Chirurgie e.V.; 20060524-20060528; Mannheim; DOC06hnod328 /20060424/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1175::f4b968327299c166afd0b7d1f2111856
http://www.egms.de/en/meetings/hnod2006/06hnod328.shtml

Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group

Autor: Fountzilas, George, Papakostas, P., Dafni, U., Makatsoris, T., Karina, M., Kalogera-Fountzila, Anna, Maniadakis, N., Aravantinos, Gerasimos, Syrigos, K., Bamias, A. T., Christodoulou, C., Economopoulos, T., Kalofonos, H. P., Nikolaou, A., Angouridakis, N., Stathopoulos, G. P., Bafaloukos, Dimitrios, Pavlidis, Nicholas, Daniilidis, J.

Publikováno v: Annals of Oncology

Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized phase III trial we compare

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f06d2f8f00f810b227da9d55f67e00
http://olympias.lib.uoi.gr/jspui/handle/123456789/19490